South Asia achieves record immunization coverage; India, Nepal lead progress: WHO-UNICEF
WHO
) and
UNICEF
for 2024.
India reduced its number of
zero-dose children
- those who have not received a single
vaccine
- by 43 per cent, from 1.6 million in 2023 to 0.9 million in 2024. Nepal achieved a 52 per cent reduction, from 23,000 to 11,000, a WHO statement said.
Pakistan also recorded its highest-ever DTP3 (Diphtheria, Tetanus, Pertussis) coverage at 87 per cent. However, Afghanistan continued to struggle, with the lowest coverage in the region and a one percentage point decline since last year, it added.
The progress marks a milestone in the region's efforts to protect every child from vaccine-preventable diseases.
"This is a proud moment for South Asia. More children are protected today than ever before, thanks to tireless frontline health workers, strong government leadership, donors' and partners' support and the unwavering trust of families," said Sanjay Wijesekera, UNICEF Regional Director for South Asia.
"But we cannot forget the millions of children who are under-vaccinated or unvaccinated. Now is the time to push further, especially into the most rural areas, to give every child his or her right to healthcare in the earliest years of life," he said.
In 2024, 92 per cent of infants in South Asia received the third dose of the
DTP vaccine
- a crucial global indicator - up two percentage points from 2023. The first-dose DTP coverage rose from 93 to 95 per cent, showing a strong recovery beyond pre-COVID levels, the statement said.
There was also a 27 per cent drop in zero-dose children across the region, from 2.5 million in 2023 to 1.8 million in 2024.
The region also made significant strides in measles control. In 2024, 93 per cent of infants received the first dose and 88 per cent the second dose of the
measles vaccine
, up from 90 per cent and 87 per cent respectively. Measles cases fell 39 per cent -- from over 90,000 in 2023 to about 55,000 this year. However, coverage still remains below the 95 per cent threshold needed to prevent outbreaks, the statement said.
"It is heartening to see WHO South-East Asia Region reach the highest ever immunization rates, surpassing the pre-pandemic up-trend. We must build on this momentum and step up efforts to reach every child with these lifesaving vaccines. Together we can, and we must," said Dr Thaksaphon Thamarangsi, Director Programme Management, WHO South-East Asia Region.
HPV vaccination
coverage for adolescent girls rose from 2 per cent in 2023 to 9 per cent in 2024. Bangladesh made significant progress, vaccinating over 7.1 million girls since launching its programme in 2023. Bhutan, Maldives, and Sri Lanka also increased their HPV coverage by 3 percentage points (91 per cent to 94 per cent), 15 points (60 per cent to 75 per cent), and 17 points (31 per cent to 48 per cent) respectively.
Nepal launched its national HPV vaccination campaign in February 2025 and has vaccinated over 1.4 million girls. India and Pakistan are expected to roll out their HPV vaccination programmes later this year, the statement said.
Behind these gains are sustained government efforts, investments, policies, and the dedication of frontline and community health workers-many of them women-alongside donor and partner support. Use of digital tools, improved data systems, and targeted outreach campaigns have also played a key role, it said.
While significant progress was made, over 2.9 million children in the region remain un- or under-vaccinated and therefore unprotected, the statement said.
With this in mind, UNICEF and WHO urged governments in South Asia to sustain political commitment, increase domestic financing for immunization, expand HPV vaccine coverage, and intensify efforts to reach zero-dose and under-vaccinated children. They also called for greater investment in frontline health workers and reinforcement of surveillance systems for vaccine-preventable diseases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
44 minutes ago
- Time of India
Study models how malaria vaccines can help mitigate climate-driven breaks in disease control
New Delhi: A study conducted in Madagascar's households has found that new malaria vaccines -- offering protection up to 10 months -- could help mitigate disruptions to disease control measures because of extreme weather events. Malaria -- a mosquito-borne infectious disease -- is a serious public health concern, with climate change-driven temperatures and rainfall creating conditions more conducive for mosquitoes to thrive and spread disease, especially in tropical countries. Researchers from the US and Madagascar in Africa said that extreme weather events, such as tropical cyclones, can hit public health infrastructure and limit people's access to malaria prevention and treatment -- this can increase infection risk, especially in high-burden regions where continuity of care and disease control is critical. However, despite concerns, data on how climate-related disruptions affect malaria control remain scarce, they said. The study, published in the journal Science, analysed 20,718 observations of malaria infection -- collected from 500 households in the African country -- before and after cyclones Batsirai (2022) and Freddy (2023) to understand how well various malaria interventions performed under the strain of extreme weather events. "In the aftermath, infection rates by the mosquito-vectored parasite increased to 10 per cent for school-aged children within three months as mosquito and malaria control activities were interrupted," the authors wrote. Brief, under-a-month-long breaks in malaria control activities, such as use of preventive medications, resulted in "rapid rebounds in infection" -- up to half of school children and over a third of younger ones were infected in high-transmission areas, the team said. Modelling strategies that may mitigate these effects in the aftermath of cyclones, the authors found that the recently introduced, WHO-recommended malaria vaccines -- 'RTS,S' and 'R21' -- could significantly reduce infection rates and help in sustaining disease control measures during breaks caused by extreme weather conditions. A vaccine coverage of 70 per cent in the population was related with a 42-52 per cent reduction in infections, the models showed. Given the figures reported by the country for routine childhood immunisation programmes, 70 per cent coverage in the population is plausible, the authors said. They wrote, "When 70 per cent of the targeted population has completed the full course for a vaccine with effectiveness of 61 to 74 per cent (reported for the R21 vaccine in phase 3 trials) before the disruptive event, a 42.7 to 51.8 per cent reduction in the expected proportion of symptomatic infections is expected." However, the team also noted that vaccines alone are not enough to arrest disease spread and that layered strategies "combining vaccines, drug-based prevention, and traditional tools like bed nets are essential, especially in high-transmission areas where malaria remains persistent".
&w=3840&q=100)
First Post
an hour ago
- First Post
Trump administration rejects WHO pandemic amendments, blasts global interference
Trump on returning to office on January 20 immediately began the withdrawal of the United States from the UN body, but the State Department said the language last year would still have been binding on the United States read more President Donald Trump's administration said Friday the United States was rejecting changes agreed last year for the World Health Organization on its pandemic response, saying they violated US sovereignty. Trump on returning to office on January 20 immediately began the withdrawal of the United States from the UN body, but the State Department said the language last year would still have been binding on the United States. Secretary of State Marco Rubio and Health and Human Services Secretary Robert F. Kennedy, who is a longtime critic of vaccines, said that the changes 'risk unwarranted interference with our national sovereign right to make health policy.' STORY CONTINUES BELOW THIS AD 'We will put Americans first in all our actions and we will not tolerate international policies that infringe on Americans' speech, privacy or personal liberties,' they said in a joint statement. Rubio and Kennedy disassociated the United States from a series of amendments to the International Health Regulations, which provide a legal framework for combatting diseases, agreed last year at the World Health Assembly in Geneva. The amendments included a stated 'commitment to solidarity and equity' in which a new group would study the needs of developing countries in future emergencies. The amendments came about after the Assembly failed at a more ambitious goal of sealing a new global agreement on pandemics. The potential treaty had drawn fierce criticism from mostly conservative voices in the United States, Britain and other countries suspicious of global efforts on disease and of vaccines. The United States, then under president Joe Biden, took part in negotiations but said it did not reach consensus as it demanded protections for US intellectual property rights on vaccine development. But Rubio's predecessor Antony Blinken welcomed the amendments as progress when he convened a meeting on global health in September with counterparts mostly from other developed countries but also India. STORY CONTINUES BELOW THIS AD In their rejection of the amendments, Rubio and Kennedy also said that the changes 'fail to adequately address the WHO's susceptibility to the political influence and censorship – most notably from China – during outbreaks.'
Hindustan Times
9 hours ago
- Hindustan Times
The world is winning the war on cancer
IN 1971 RICHARD NIXON, then America's president, announced a 'war on cancer'. Just two years earlier the Apollo programme had combined big science and big government to put astronauts on the Moon, so hopes were high. Some optimistic doctors talked of a cure for cancer within a few years. They were wrong. Today every adult has had cancer, knows someone who has, or both. Half of men and a third of women in rich countries can expect to suffer from it at some point in their lives. In America, where it is the second-most-common cause of death, just behind heart disease, it kills around 600,000 people a year. Worldwide, it is responsible for about one in six of all deaths. If your criterion for success was a cure within a decade—or even two or three or four—then you might conclude that the war on cancer has been lost. In fact, things are better than many realise. The progress is plain from the data and there is every reason to think it will continue. Cancer is related to age. If you strip out longer lifespans, it becomes clear that in the rich world the early 1990s were an inflection point. Since then, the age-adjusted death rate has been falling, slowly but steadily, year after year. In America the rate is now about a third lower than in the 1990s. The trend is similar in other developed countries. What some scientists hoped would be a blitzkrieg has turned out to be a steady but successful war of attrition. Some victories have been spectacular. Childhood leukaemia used to be virtually a death sentence; now it has a five-year survival rate above 90%. Yet because cancer is not one illness, but a whole category, much of the progress has come not from big breakthroughs, but thousands of smaller advances in screening, surgery and drugs. Future gains will come from three main sources. Some will come by applying lessons from the rich world all across the globe. The overlooked success story in the fight against cancer has been prevention—perhaps because cancers that never happen are less visible than those that are cured. For example, smoking rates have plummeted in rich countries. That has probably prevented more than 3m cancer deaths since 1975 in America alone. Because smoking still causes one in five cancer deaths around the world, anti-tobacco drives in poor and middle-income countries, where smoking remains common, stand to do an enormous amount of good. Another source of progress will be cheaper medicines and extra wealth to pay for them. Cervical cancer is one of the most common cancers in women. Almost all cases are the delayed side-effect of infection with the human papillomavirus (HPV), a bug. In 2008 Britain began offering a newly developed HPV vaccine to teenage girls. A decade and a half later, rates of cervical cancer among women in their 20s are down by 90%, and British health officials talk of virtually eradicating cervical cancer by 2040. The original HPV vaccine was relatively expensive. But a cheaper version developed in India now underpins a mass-vaccination campaign in that country, too. And the last source of progress will be the clinical application of fresh science. This comes in two steps: identifying who is most at risk of developing a cancer, and then finding ways to stop the disease in its tracks. As we report this week, both hold promise. Scientists already know of genetic variants that predispose their carriers to certain kinds of cancer, such as a faulty BRCA-1 gene that raises the risk of breast or prostate cancer. However, less than half of all cancer patients have a known risk factor. Similarly, only some pre-cancerous cells turn malignant. For example, bowel cancers tend to emerge from polyps, but only 5-10% of polyps become cancerous. The aim is to untangle this confusion in order to identify patients very early, when treatment is most effective. That work draws on huge biobanks of tissue samples and on the ability to watch genes switch on and off in living cells—impossible even a decade ago. Armed with new biomarkers in blood or breath and a deeper understanding of how combinations of genes and environmental exposure predispose people to develop cancers, physicians can target those who would benefit from treatment. That is important to prevent people undergoing needless surgery, chemo- and radiation therapy, at vast expense and with severe side-effects. Having worked out whom to treat, doctors can make use of an expanding arsenal of therapies. Some cheap drugs seem to act as cancer prophylactics. Aspirin, a painkiller, seems to cut the risk of bowel cancer in half when given to those with Lynch syndrome, a genetic disorder that predisposes sufferers to some types of cancer. Metformin, a cheap diabetes drug, cuts the risk of recurrence in women who have been treated for a particular type of breast cancer. GLP-1 receptor agonists such as Ozempic show promise, too. Alongside the mainstays of surgery, chemotherapy and radiotherapy a new technique is emerging that harnesses the power of the immune system. The idea is to boost the body's own ability to attack cancerous cells. Some vaccines—perhaps genetically tailored to individual patients—can target a cancer that is already established. Others, acting more like broad vaccines used against diseases such as the flu, could target pre-cancerous cells. Vaccines of this sort for breast and colon cancer are in clinical trials. Bucking onco Good news often goes unreported, especially if it happens gradually. That is the story of the war on cancer. Not everything is perfect: treatments are costly, drug firms worry about being sued for side-effects when treating people for diseases they do not yet have, and the Trump administration is planning steep cuts to the National Cancer Institute—setting back the science and putting off a generation of researchers. But costs will fall, treatments will find their way to market and work goes on in Europe and China, which this year overtook America as the main source of cancer research. That is why the age-adjusted death rate will continue falling, year after year. For subscribers only: to see how we design each week's cover, sign up to our weekly Cover Story newsletter.
